{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:31:00Z","timestamp":1794274260541,"version":"4.9.0"},"reference-count":140,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":47,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Breast cancer remains a leading cause of death worldwide. Although chemotherapy reduces primary and metastatic tumour burden, persisting drug-tolerant tumour cell populations, known as minimal residual disease (MRD), pose a significant risk of recurrence and therapy resistance. In this study, we describe the spatiotemporal organisation of therapy response and MRD in BRCA1;p53-deficient mouse mammary tumours and human clinical samples. By integrating single-cell RNA sequencing, spatial transcriptomics, and imaging mass cytometry across multiple treatment timepoints, we characterise dynamic interactions between tumour cell subpopulations and their surrounding microenvironment. Our multiomic analysis uncovers a distinct, chemotherapy-tolerant epithelial-mesenchymal transition (EMT) cancer cell population that displays a conserved expression programme in human BRCA1-deficient tumours, significantly correlates with adverse clinical outcomes, and can be pharmacologically targeted in preclinical models. We reveal the spatial distribution of residual EMT-like tumour cells within discrete anatomical niches, providing a framework for understanding the persistence of MRD and potential therapeutic vulnerabilities.<\/jats:p>","DOI":"10.1038\/s41467-026-74125-6","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T17:46:37Z","timestamp":1781199997000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Spatiotemporal organisation of residual disease in mouse and human BRCA1-deficient mammary tumours and breast cancer"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5783-5314","authenticated-orcid":false,"given":"Demeter","family":"T\u00far\u00f3s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2426-3101","authenticated-orcid":false,"given":"Morgane","family":"Decollogny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Moyseos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Chanfon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Siffert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Bousmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6454-0503","authenticated-orcid":false,"given":"Lou","family":"Romanens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Tille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5881-9383","authenticated-orcid":false,"given":"Olivier","family":"Tredan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Intidhar","family":"Labidi-Galy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5482-9023","authenticated-orcid":false,"given":"Alberto","family":"Valdeolivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2044-9844","authenticated-orcid":false,"given":"Sven","family":"Rottenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"74125_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA: A Cancer J. Clin. 73, 17\u201348 (2023).","journal-title":"CA: A Cancer J. Clin."},{"key":"74125_CR2","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3390\/medicina57010062","volume":"57","author":"SA Dass","year":"2021","unstructured":"Dass, S. A. et al. Triple negative breast cancer: a review of present and future diagnostic modalities. Medicina 57, 62 (2021).","journal-title":"Medicina"},{"key":"74125_CR3","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1146\/annurev-pathol-042420-093238","volume":"17","author":"F Derakhshan","year":"2022","unstructured":"Derakhshan, F. & Reis-Filho, J. S. Pathogenesis of triple-negative breast cancer. Annu. Rev. Pathol.: Mech. Dis. 17, 181\u2013204 (2022).","journal-title":"Annu. Rev. Pathol.: Mech. Dis."},{"key":"74125_CR4","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(14)70160-3","volume":"15","author":"Gvon Minckwitz","year":"2014","unstructured":"Minckwitz, G. von et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet. Oncol. 15, 747\u2013756 (2014).","journal-title":"Lancet. Oncol."},{"key":"74125_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1200\/JCO.2014.57.0572","volume":"33","author":"WM Sikov","year":"2014","unstructured":"Sikov, W. M. et al. Impact of the addition of carboplatin and\/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J. Clin. Oncol. 33, 13\u201321 (2014).","journal-title":"J. Clin. Oncol."},{"key":"74125_CR6","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S1470-2045(18)30111-6","volume":"19","author":"S Loibl","year":"2018","unstructured":"Loibl, S. et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet. Oncol. 19, 497\u2013509 (2018).","journal-title":"Lancet. Oncol."},{"key":"74125_CR7","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid, P. et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N. Engl. J. Med. 379, 2108\u20132121 (2018).","journal-title":"N. Engl. J. Med."},{"key":"74125_CR8","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid, P. et al. Pembrolizumab for early triple-negative breast cancer. N. Engl. J. Med. 382, 810\u2013821 (2020).","journal-title":"N. Engl. J. Med."},{"key":"74125_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-021-00219-7","volume":"7","author":"J Foldi","year":"2021","unstructured":"Foldi, J. et al. Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin\/cyclophosphamide in triple-negative breast cancer. npj Breast Cancer 7, 9 (2021).","journal-title":"npj Breast Cancer"},{"key":"74125_CR10","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.annonc.2024.02.002","volume":"35","author":"L Pusztai","year":"2024","unstructured":"Pusztai, L. et al. Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522\u2606. Ann. Oncol. 35, 429\u2013436 (2024).","journal-title":"Ann. Oncol."},{"key":"74125_CR11","doi-asserted-by":"publisher","first-page":"154428","DOI":"10.1016\/j.prp.2023.154428","volume":"245","author":"S Cui","year":"2023","unstructured":"Cui, S., Liu, W., Wang, W., Miao, K. & Guan, X. Advances in the diagnosis and prognosis of minimal residual lesions of breast cancer. Pathol. Res. Pr. 245, 154428 (2023).","journal-title":"Pathol. Res. Pr."},{"key":"74125_CR12","doi-asserted-by":"publisher","first-page":"120066","DOI":"10.1098\/rsob.120066","volume":"2","author":"P Borst","year":"2012","unstructured":"Borst, P. Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what? Open Biol. 2, 120066 (2012).","journal-title":"Open Biol."},{"key":"74125_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10690","volume":"7","author":"M Ramirez","year":"2016","unstructured":"Ramirez, M. et al. Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells. Nat. Commun. 7, 10690 (2016).","journal-title":"Nat. Commun."},{"key":"74125_CR14","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.3390\/cancers13051118","volume":"13","author":"GD Conti","year":"2021","unstructured":"Conti, G. D., Dias, M. H. & Bernards, R. Fighting drug resistance through the targeting of drug-tolerant persister cells. Cancers 13, 1118 (2021).","journal-title":"Cancers"},{"key":"74125_CR15","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.trecan.2024.02.002","volume":"10","author":"M Decollogny","year":"2024","unstructured":"Decollogny, M. & Rottenberg, S. Persisting cancer cells are different from bacterial persisters. Trends Cancer 10, 393\u2013406 (2024).","journal-title":"Trends Cancer"},{"key":"74125_CR16","doi-asserted-by":"publisher","first-page":"7020","DOI":"10.1158\/1078-0432.CCR-17-1279","volume":"23","author":"M Pajic","year":"2017","unstructured":"Pajic, M. et al. Selected alkylating agents can overcome drug tolerance of G0-like tumor cells and eradicate BRCA1-deficient mammary tumors in mice. Clin. Cancer Res. 23, 7020\u20137033 (2017).","journal-title":"Clin. Cancer Res."},{"key":"74125_CR17","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrc3793","volume":"14","author":"MS Sosa","year":"2014","unstructured":"Sosa, M. S., Bragado, P. & Aguirre-Ghiso, J. A. Mechanisms of disseminated cancer cell dormancy: an awakening field. Nat. Rev. Cancer 14, 611\u2013622 (2014).","journal-title":"Nat. Rev. Cancer"},{"key":"74125_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-021-01416-9","volume":"23","author":"JR Ruth","year":"2021","unstructured":"Ruth, J. R. et al. Cellular dormancy in minimal residual disease following targeted therapy. Breast Cancer Res. 23, 63 (2021).","journal-title":"Breast Cancer Res"},{"key":"74125_CR19","doi-asserted-by":"publisher","first-page":"a041331","DOI":"10.1101\/cshperspect.a041331","volume":"13","author":"E Dalla","year":"2023","unstructured":"Dalla, E., Sreekumar, A., Aguirre-Ghiso, J. A. & Chodosh, L. A. Dormancy in Breast Cancer. Cold Spring Harb. Perspect. Med. 13, a041331 (2023).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"74125_CR20","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/s41586-021-03796-6","volume":"596","author":"Y Oren","year":"2021","unstructured":"Oren, Y. et al. Cycling cancer persister cells arise from lineages with distinct programs. Nature 596, 576\u2013582 (2021).","journal-title":"Nature"},{"key":"74125_CR21","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ccell.2020.12.002","volume":"39","author":"E Dhimolea","year":"2021","unstructured":"Dhimolea, E. et al. An embryonic diapause-like adaptation with suppressed myc activity enables tumor treatment persistence. Cancer Cell 39, 240\u2013256 (2021).","journal-title":"Cancer Cell"},{"key":"74125_CR22","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.cell.2020.11.018","volume":"184","author":"SK Rehman","year":"2021","unstructured":"Rehman, S. K. et al. Colorectal cancer cells enter a diapause-like DTP state to survive chemotherapy. Cell 184, 226\u2013242 (2021).","journal-title":"Cell"},{"key":"74125_CR23","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","volume":"141","author":"SV Sharma","year":"2010","unstructured":"Sharma, S. V. et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69\u201380 (2010).","journal-title":"Cell"},{"key":"74125_CR24","doi-asserted-by":"crossref","unstructured":"Echeverria, G. V. et al. Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state. Sci. Transl. Med. 11, eaav0936 (2019).","DOI":"10.1126\/scitranslmed.aav0936"},{"key":"74125_CR25","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/bs.acr.2022.12.006","volume":"158","author":"N Mani","year":"2023","unstructured":"Mani, N., Daiya, A., Chowdhury, R., Mukherjee, S. & Chowdhury, S. Epigenetic adaptations in drug-tolerant tumor cells. Adv. Cancer Res. 158, 293\u2013335 (2023).","journal-title":"Adv. Cancer Res"},{"key":"74125_CR26","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nature24297","volume":"551","author":"MJ Hangauer","year":"2017","unstructured":"Hangauer, M. J. et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature 551, 247\u2013250 (2017).","journal-title":"Nature"},{"key":"74125_CR27","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1172\/JCI89914","volume":"127","author":"KM Havas","year":"2017","unstructured":"Havas, K. M. et al. Metabolic shifts in residual breast cancer drive tumor recurrence. J. Clin. Invest 127, 2091\u20132105 (2017).","journal-title":"J. Clin. Invest"},{"key":"74125_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04070-6","volume":"9","author":"L Vera-Ramirez","year":"2018","unstructured":"Vera-Ramirez, L., Vodnala, S. K., Nini, R., Hunter, K. W. & Green, J. E. Autophagy promotes the survival of dormant breast cancer cells and metastatic tumour recurrence. Nat. Commun. 9, 1944 (2018).","journal-title":"Nat. Commun."},{"key":"74125_CR29","doi-asserted-by":"publisher","first-page":"eadj7540","DOI":"10.1126\/sciadv.adj7540","volume":"10","author":"ED Sunassee","year":"2024","unstructured":"Sunassee, E. D. et al. Optical imaging reveals chemotherapy-induced metabolic reprogramming of residual disease and recurrence. Sci. Adv. 10, eadj7540 (2024).","journal-title":"Sci. Adv."},{"key":"74125_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-021-00200-4","volume":"5","author":"G Wang","year":"2021","unstructured":"Wang, G. et al. The pan-cancer landscape of crosstalk between epithelial-mesenchymal transition and immune evasion relevant to prognosis and immunotherapy response. npj Precis. Oncol. 5, 56 (2021).","journal-title":"npj Precis. Oncol."},{"key":"74125_CR31","doi-asserted-by":"publisher","first-page":"12117","DOI":"10.1073\/pnas.0702955104","volume":"104","author":"S Rottenberg","year":"2007","unstructured":"Rottenberg, S. et al. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc. Natl. Acad. Sci. 104, 12117\u201312122 (2007).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"74125_CR32","doi-asserted-by":"publisher","first-page":"17079","DOI":"10.1073\/pnas.0806092105","volume":"105","author":"S Rottenberg","year":"2008","unstructured":"Rottenberg, S. et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc. Natl. Acad. Sci. 105, 17079\u201317084 (2008).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"74125_CR33","doi-asserted-by":"publisher","first-page":"12111","DOI":"10.1073\/pnas.0702969104","volume":"104","author":"X Liu","year":"2007","unstructured":"Liu, X. et al. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc. Natl. Acad. Sci. 104, 12111\u201312116 (2007).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"74125_CR34","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/s42003-021-02201-2","volume":"4","author":"K Saeki","year":"2021","unstructured":"Saeki, K. et al. Mammary cell gene expression atlas links epithelial cell remodeling events to breast carcinogenesis. Commun. Biol. 4, 660 (2021).","journal-title":"Commun. Biol."},{"key":"74125_CR35","doi-asserted-by":"publisher","first-page":"108566","DOI":"10.1016\/j.celrep.2020.108566","volume":"33","author":"CM-C Li","year":"2020","unstructured":"Li, C. M.-C. et al. Aging-Associated Alterations in Mammary Epithelia and Stroma Revealed by Single-Cell RNA Sequencing. Cell Rep. 33, 108566 (2020).","journal-title":"Cell Rep."},{"key":"74125_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29366-6","volume":"13","author":"J Qi","year":"2022","unstructured":"Qi, J. et al. Single-cell and spatial analysis reveal interaction of FAP+ fibroblasts and SPP1+ macrophages in colorectal cancer. Nat. Commun. 13, 1742 (2022).","journal-title":"Nat. Commun."},{"key":"74125_CR37","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1177\/0300985820980049","volume":"58","author":"TA Donovan","year":"2021","unstructured":"Donovan, T. A. et al. Mitotic Figures\u2014Normal, Atypical, and Imposters: A Guide to Identification. Vet. Pathol. 58, 243\u2013257 (2021).","journal-title":"Vet. Pathol."},{"key":"74125_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05215-8","volume":"13","author":"N Wu","year":"2022","unstructured":"Wu, N. et al. Cathepsin K regulates the tumor growth and metastasis by IL-17\/CTSK\/EMT axis and mediates M2 macrophage polarization in castration-resistant prostate cancer. Cell Death Dis. 13, 813 (2022).","journal-title":"Cell Death Dis."},{"key":"74125_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-018-0713-x","volume":"18","author":"S-H Li","year":"2018","unstructured":"Li, S.-H. et al. An actin-binding protein ESPN is an independent prognosticator and regulates cell growth for esophageal squamous cell carcinoma. Cancer Cell Int. 18, 219 (2018).","journal-title":"Cancer Cell Int"},{"key":"74125_CR40","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41416-023-02546-x","volume":"130","author":"F Cai","year":"2024","unstructured":"Cai, F. et al. EGLN3 attenuates gastric cancer cell malignant characteristics by inhibiting JMJD8\/NF-\u03baB signalling activation independent of hydroxylase activity. Br. J. Cancer 130, 597\u2013612 (2024).","journal-title":"Br. J. Cancer"},{"key":"74125_CR41","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13045-018-0645-x","volume":"11","author":"M Si","year":"2018","unstructured":"Si, M. & Lang, J. The roles of metallothioneins in carcinogenesis. J. Hematol. Oncol. 11, 107 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"74125_CR42","doi-asserted-by":"publisher","first-page":"1174535","DOI":"10.3389\/fcell.2023.1174535","volume":"11","author":"L Shen","year":"2023","unstructured":"Shen, L. et al. Pan-cancer and single-cell analysis reveal the prognostic value and immune response of NQO1. Front. Cell Dev. Biol. 11, 1174535 (2023).","journal-title":"Front. Cell Dev. Biol."},{"key":"74125_CR43","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1038\/s42003-024-07165-7","volume":"7","author":"D T\u00far\u00f3s","year":"2024","unstructured":"T\u00far\u00f3s, D., Vasiljevic, J., Hahn, K., Rottenberg, S. & Valdeolivas, A. Chrysalis: decoding tissue compartments in spatial transcriptomics with archetypal analysis. Commun. Biol. 7, 1520 (2024).","journal-title":"Commun. Biol."},{"key":"74125_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02391-6","volume":"9","author":"M Schubert","year":"2018","unstructured":"Schubert, M. et al. Perturbation-response genes reveal signaling footprints in cancer gene expression. Nat. Commun. 9, 20 (2018).","journal-title":"Nat. Commun."},{"key":"74125_CR45","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1038\/nrc2465","volume":"8","author":"RW Johnstone","year":"2008","unstructured":"Johnstone, R. W., Frew, A. J. & Smyth, M. J. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat. Rev. Cancer 8, 782\u2013798 (2008).","journal-title":"Nat. Rev. Cancer"},{"key":"74125_CR46","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/bjc.2015.233","volume":"113","author":"SJ Thomas","year":"2015","unstructured":"Thomas, S. J., Snowden, J. A., Zeidler, M. P. & Danson, S. J. The role of JAK\/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours. Br. J. Cancer 113, 365\u2013371 (2015).","journal-title":"Br. J. Cancer"},{"key":"74125_CR47","unstructured":"Sibai, M. et al. The spatial landscape of cancer hallmarks reveals patterns of tumor ecological dynamics and drug sensitivity. Cell Reports 44, 115229 (2025)."},{"key":"74125_CR48","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ccell.2019.12.006","volume":"37","author":"KJ Kurppa","year":"2020","unstructured":"Kurppa, K. J. et al. Treatment-induced tumor dormancy through YAP-mediated transcriptional reprogramming of the apoptotic pathway. Cancer Cell 37, 104\u2013122.e12 (2020).","journal-title":"Cancer Cell"},{"key":"74125_CR49","doi-asserted-by":"publisher","unstructured":"Duy, C. et al. Chemotherapy induces senescence-like resilient cells capable of initiating AML recurrence. Cancer Discov. https:\/\/doi.org\/10.1158\/2159-8290.cd-20-1375 (2021).","DOI":"10.1158\/2159-8290.cd-20-1375"},{"key":"74125_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32552-1","volume":"13","author":"D Saul","year":"2022","unstructured":"Saul, D. et al. A new gene set identifies senescent cells and predicts senescence-associated pathways across tissues. Nat. Commun. 13, 4827 (2022).","journal-title":"Nat. Commun."},{"key":"74125_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01793-z","volume":"22","author":"A Akhmetkaliyev","year":"2023","unstructured":"Akhmetkaliyev, A., Alibrahim, N., Shafiee, D. & Tulchinsky, E. EMT\/MET plasticity in cancer and Go-or-Grow decisions in quiescence: the two sides of the same coin? Mol. Cancer 22, 90 (2023).","journal-title":"Mol. Cancer"},{"key":"74125_CR52","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1126\/science.aav4474","volume":"366","author":"M Russo","year":"2019","unstructured":"Russo, M. et al. Adaptive mutability of colorectal cancers in response to targeted therapies. Science 366, 1473\u20131480 (2019).","journal-title":"Science"},{"key":"74125_CR53","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The molecular signatures database hallmark gene set collection. Cell Syst. 1, 417\u2013425 (2015).","journal-title":"Cell Syst."},{"key":"74125_CR54","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/75556","volume":"25","author":"M Ashburner","year":"2000","unstructured":"Ashburner, M. et al. Gene Ontology: tool for the unification of biology. Nat. Genet. 25, 25\u201329 (2000).","journal-title":"Nat. Genet."},{"key":"74125_CR55","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1038\/s41556-024-01469-w","volume":"26","author":"D Dimitrov","year":"2024","unstructured":"Dimitrov, D. et al. LIANA+ provides an all-in-one framework for cell\u2013cell communication inference. Nat. Cell Biol. 26, 1613\u20131622 (2024).","journal-title":"Nat. Cell Biol."},{"key":"74125_CR56","doi-asserted-by":"publisher","first-page":"956926","DOI":"10.3389\/fonc.2022.956926","volume":"12","author":"A Sirvent","year":"2022","unstructured":"Sirvent, A., Espie, K., Papadopoulou, E., Naim, D. & Roche, S. New functions of DDR1 collagen receptor in tumor dormancy, immune exclusion and therapeutic resistance. Front. Oncol. 12, 956926 (2022).","journal-title":"Front. Oncol."},{"key":"74125_CR57","doi-asserted-by":"crossref","unstructured":"Galifi, C. A. et al. Insulin-like growth factor 1 receptor regulates breast cancer cell adhesion through beta-1 integrin. Front. Endocrinol. 17, 1701560 (2026).","DOI":"10.3389\/fendo.2026.1701560"},{"key":"74125_CR58","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s43556-025-00327-x","volume":"6","author":"J Liang","year":"2025","unstructured":"Liang, J., Pan, Y., Yang, J., Zeng, D. & Li, J. WNT signaling in cancer: molecular mechanisms and potential therapies. Mol. Biomed. 6, 83 (2025).","journal-title":"Mol. Biomed."},{"key":"74125_CR59","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1038\/s41388-025-03447-4","volume":"44","author":"C Berenguier","year":"2025","unstructured":"Berenguier, C. et al. Cancer-associated loss-of-function mutations in KCNQ1 enhance Wnt\/\u03b2-catenin signalling disrupting epithelial homeostasis. Oncogene 44, 2715\u20132729 (2025).","journal-title":"Oncogene"},{"key":"74125_CR60","doi-asserted-by":"publisher","first-page":"13125","DOI":"10.1096\/fj.202000380RR","volume":"34","author":"L Chen","year":"2020","unstructured":"Chen, L. et al. The role of CD44 in pathological angiogenesis. FASEB J. 34, 13125\u201313139 (2020).","journal-title":"FASEB J."},{"key":"74125_CR61","doi-asserted-by":"publisher","first-page":"e007447","DOI":"10.1136\/jitc-2023-007447","volume":"11","author":"L Lu","year":"2023","unstructured":"Lu, L. et al. Targeting integrin \u03b15 in fibroblasts potentiates colorectal cancer response to PD-L1 blockade by affecting extracellular-matrix deposition. J. Immunother. Cancer 11, e007447 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"74125_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-01152-9","volume":"9","author":"Y Huang","year":"2025","unstructured":"Huang, Y. & Fang, W. TREM2-mediated regulation of myeloid cells in the tumor microenvironment: new insights and therapeutic prospects. npj Precis. Oncol. 9, 359 (2025).","journal-title":"npj Precis. Oncol."},{"key":"74125_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40068-5","volume":"14","author":"CC Liu","year":"2023","unstructured":"Liu, C. C. et al. Robust phenotyping of highly multiplexed tissue imaging data using pixel-level clustering. Nat. Commun. 14, 4618 (2023).","journal-title":"Nat. Commun."},{"key":"74125_CR64","doi-asserted-by":"publisher","first-page":"030001","DOI":"10.1088\/1674-1137\/abddae","volume":"45","author":"FG Kondev","year":"2021","unstructured":"Kondev, F. G., Wang, M., Huang, W. J., Naimi, S. & Audi, G. The NUBASE2020 evaluation of nuclear physics properties. Chin. Phys. C. 45, 030001 (2021).","journal-title":"Chin. Phys. C."},{"key":"74125_CR65","doi-asserted-by":"publisher","first-page":"7265","DOI":"10.1038\/sj.onc.1206933","volume":"22","author":"ZH Siddik","year":"2003","unstructured":"Siddik, Z. H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22, 7265\u20137279 (2003).","journal-title":"Oncogene"},{"key":"74125_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/srep36641","volume":"6","author":"Q Chang","year":"2016","unstructured":"Chang, Q. et al. Biodistribution of cisplatin revealed by imaging mass cytometry identifies extensive collagen binding in tumor and normal tissues. Sci. Rep. 6, 36641 (2016).","journal-title":"Sci. Rep."},{"key":"74125_CR67","doi-asserted-by":"publisher","first-page":"5384","DOI":"10.1158\/1078-0432.CCR-14-1298","volume":"20","author":"AR Biasi","year":"2014","unstructured":"Biasi, A. R., de, Villena-Vargas, J. & Adusumilli, P. S. Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence. Clin. Cancer Res. 20, 5384\u20135391 (2014).","journal-title":"Clin. Cancer Res."},{"key":"74125_CR68","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-022-02663-5","volume":"23","author":"J Tanevski","year":"2022","unstructured":"Tanevski, J., Flores, R. O. R., Gabor, A., Schapiro, D. & Saez-Rodriguez, J. Explainable multiview framework for dissecting spatial relationships from highly multiplexed data. Genome Biol. 23, 97 (2022).","journal-title":"Genome Biol."},{"key":"74125_CR69","doi-asserted-by":"publisher","first-page":"4564","DOI":"10.1158\/1078-0432.CCR-08-0121","volume":"14","author":"A Belkhiri","year":"2008","unstructured":"Belkhiri, A. et al. Expression of t-DARPP mediates trastuzumab resistance in breast cancer cells. Clin. Cancer Res. 14, 4564\u20134571 (2008).","journal-title":"Clin. Cancer Res."},{"key":"74125_CR70","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1091\/mbc.E16-02-0101","volume":"27","author":"N Bendris","year":"2016","unstructured":"Bendris, N. et al. SNX9 promotes metastasis by enhancing cancer cell invasion via differential regulation of RhoGTPases. Mol. Biol. Cell 27, 1409\u20131419 (2016).","journal-title":"Mol. Biol. Cell"},{"key":"74125_CR71","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-015-0131-9","volume":"7","author":"LH Saal","year":"2015","unstructured":"Saal, L. H. et al. The Sweden Cancerome Analysis Network - Breast (SCAN-B) Initiative: a large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine. Genome Med. 7, 20 (2015).","journal-title":"Genome Med"},{"key":"74125_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11479","volume":"7","author":"B Pereira","year":"2016","unstructured":"Pereira, B. et al. The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes. Nat. Commun. 7, 11479 (2016).","journal-title":"Nat. Commun."},{"key":"74125_CR73","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/ng.2764","volume":"45","author":"K Chang","year":"2013","unstructured":"Chang, K. et al. The cancer genome Atlas pan-cancer analysis project. Nat. Genet. 45, 1113\u20131120 (2013).","journal-title":"Nat. Genet."},{"key":"74125_CR74","doi-asserted-by":"publisher","first-page":"CMO.S29462","DOI":"10.4137\/CMO.S29462","volume":"9","author":"H Ahmed","year":"2015","unstructured":"Ahmed, H. & Alsadek, D. M. M. Galectin-3 as a potential target to prevent cancer metastasis. Clin. Med. Insights: Oncol. 9, CMO.S29462 (2015).","journal-title":"Clin. Med. Insights: Oncol."},{"key":"74125_CR75","doi-asserted-by":"publisher","first-page":"6086","DOI":"10.1158\/1078-0432.CCR-18-3870","volume":"26","author":"P Navarro","year":"2020","unstructured":"Navarro, P., Mart\u00ednez-Bosch, N., Blidner, A. G. & Rabinovich, G. A. Impact of galectins in resistance to anticancer therapies. Clin. Cancer Res. 26, 6086\u20136101 (2020).","journal-title":"Clin. Cancer Res."},{"key":"74125_CR76","doi-asserted-by":"crossref","unstructured":"Seguin, L. et al. Galectin-3, a druggable vulnerability for KRAS-addicted cancers. Cancer Discov. 7, CD-17-0539 (2017).","DOI":"10.1158\/2159-8290.CD-17-0539"},{"key":"74125_CR77","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/nmeth.4535","volume":"15","author":"AA Duarte","year":"2018","unstructured":"Duarte, A. A. et al. BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance. Nat. Methods 15, 134\u2013140 (2018).","journal-title":"Nat. Methods"},{"key":"74125_CR78","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","volume":"20","author":"S Zheng","year":"2022","unstructured":"Zheng, S. et al. SynergyFinder plus: toward better interpretation and annotation of drug combination screening datasets. Genom., Proteom. Bioinform. 20, 587\u2013596 (2022).","journal-title":"Genom., Proteom. Bioinform."},{"key":"74125_CR79","doi-asserted-by":"publisher","first-page":"6853","DOI":"10.3390\/ijms25136853","volume":"25","author":"S Foutadakis","year":"2024","unstructured":"Foutadakis, S., Kordias, D., Vatsellas, G. & Magklara, A. Identification of new chemoresistance-associated genes in triple-negative breast cancer by single-cell transcriptomic analysis. Int. J. Mol. Sci. 25, 6853 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"74125_CR80","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1158\/1541-7786.MCR-20-0067","volume":"18","author":"AJ Gooding","year":"2020","unstructured":"Gooding, A. J. & Schiemann, W. P. Epithelial\u2013mesenchymal transition programs and cancer stem cell phenotypes: mediators of breast cancer therapy resistance. Mol. Cancer Res. 18, 1257\u20131270 (2020).","journal-title":"Mol. Cancer Res."},{"key":"74125_CR81","doi-asserted-by":"publisher","first-page":"3982","DOI":"10.1158\/0008-5472.CAN-16-3292","volume":"77","author":"A Dongre","year":"2017","unstructured":"Dongre, A. et al. Epithelial-to-mesenchymal transition contributes to immunosuppression in breast carcinomas. Cancer Res. 77, 3982\u20133989 (2017).","journal-title":"Cancer Res"},{"key":"74125_CR82","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41580-018-0080-4","volume":"20","author":"A Dongre","year":"2019","unstructured":"Dongre, A. & Weinberg, R. A. New insights into the mechanisms of epithelial\u2013mesenchymal transition and implications for cancer. Nat. Rev. Mol. Cell Biol. 20, 69\u201384 (2019).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"74125_CR83","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1007\/s00204-021-03063-7","volume":"95","author":"JDL Rivas","year":"2021","unstructured":"Rivas, J. D. L. et al. Cancer drug resistance induced by EMT: novel therapeutic strategies. Arch. Toxicol. 95, 2279\u20132297 (2021).","journal-title":"Arch. Toxicol."},{"key":"74125_CR84","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13045-022-01347-8","volume":"15","author":"Y Huang","year":"2022","unstructured":"Huang, Y., Hong, W. & Wei, X. The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis. J. Hematol. Oncol. 15, 129 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"74125_CR85","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrclinonc.2017.44","volume":"14","author":"T Shibue","year":"2017","unstructured":"Shibue, T. & Weinberg, R. A. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat. Rev. Clin. Oncol. 14, 611\u2013629 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"74125_CR86","doi-asserted-by":"publisher","first-page":"e179","DOI":"10.1038\/cddis.2011.61","volume":"2","author":"M Saxena","year":"2011","unstructured":"Saxena, M., Stephens, M. A., Pathak, H. & Rangarajan, A. Transcription factors that mediate epithelial\u2013mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. Cell Death Dis. 2, e179\u2013e179 (2011).","journal-title":"Cell Death Dis."},{"key":"74125_CR87","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1158\/2159-8290.CD-13-0945","volume":"4","author":"Y Feng","year":"2014","unstructured":"Feng, Y. et al. Epithelial-to-mesenchymal transition activates PERK\u2013eIF2\u03b1 and sensitizes cells to endoplasmic reticulum stress. Cancer Discov. 4, 702\u2013715 (2014).","journal-title":"Cancer Discov."},{"key":"74125_CR88","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s10555-023-10162-7","volume":"43","author":"N Ebrahimi","year":"2024","unstructured":"Ebrahimi, N. et al. Harnessing function of EMT in cancer drug resistance: a metastasis regulator determines chemotherapy response. Cancer Metastasis Rev. 43, 457\u2013479 (2024).","journal-title":"Cancer Metastasis Rev."},{"key":"74125_CR89","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41586-023-05838-7","volume":"616","author":"M Debaugnies","year":"2023","unstructured":"Debaugnies, M. et al. RHOJ controls EMT-associated resistance to chemotherapy. Nature 616, 168\u2013175 (2023).","journal-title":"Nature"},{"key":"74125_CR90","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3389\/fonc.2020.00587","volume":"10","author":"V Fedele","year":"2020","unstructured":"Fedele, V. & Melisi, D. Permissive State of EMT: The Role of Immune Cell Compartment. Front. Oncol. 10, 587 (2020).","journal-title":"Front. Oncol."},{"key":"74125_CR91","doi-asserted-by":"publisher","first-page":"720","DOI":"10.4143\/crt.2023.468","volume":"55","author":"H-Y Min","year":"2023","unstructured":"Min, H.-Y. & Lee, H.-Y. Cellular Dormancy in Cancer - Mechanisms and Potential Targeting Strategies. Cancer Res. Treat. 55, 720\u2013736 (2023).","journal-title":"Cancer Res. Treat."},{"key":"74125_CR92","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3389\/fimmu.2014.00402","volume":"5","author":"SS Bohlson","year":"2014","unstructured":"Bohlson, S. S., O\u2019Conner, S. D., Hulsebus, H. J., Ho, M.-M. & Fraser, D. A. Complement, C1q, and C1q-Related Molecules Regulate Macrophage Polarization. Front. Immunol. 5, 402 (2014).","journal-title":"Front. Immunol."},{"key":"74125_CR93","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.canlet.2019.12.024","volume":"472","author":"W Liu","year":"2020","unstructured":"Liu, W. et al. Cisplatin-stimulated macrophages promote ovarian cancer migration via the CCL20-CCR6 axis. Cancer Lett. 472, 59\u201369 (2020).","journal-title":"Cancer Lett."},{"key":"74125_CR94","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead, P. et al. QuPath: Open source software for digital pathology image analysis. Sci. Rep. 7, 16878 (2017).","journal-title":"Sci. Rep."},{"key":"74125_CR95","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/cyto.a.24714","volume":"103","author":"F Birrer","year":"2023","unstructured":"Birrer, F., Brodie, T. & Stroka, D. OMIP-088: Twenty-target imaging mass cytometry panel for major cell populations in mouse formalin fixed paraffin embedded liver. Cytom. Part A 103, 189\u2013192 (2023).","journal-title":"Cytom. Part A"},{"key":"74125_CR96","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-017-1382-0","volume":"19","author":"FA Wolf","year":"2018","unstructured":"Wolf, F. A., Angerer, P. & Theis, F. J. SCANPY: large-scale single-cell gene expression data analysis. Genome Biol. 19, 15 (2018).","journal-title":"Genome Biol."},{"key":"74125_CR97","doi-asserted-by":"publisher","first-page":"1737369","DOI":"10.1080\/2162402X.2020.1737369","volume":"9","author":"SJ Carmona","year":"2020","unstructured":"Carmona, S. J., Siddiqui, I., Bilous, M., Held, W. & Gfeller, D. Deciphering the transcriptomic landscape of tumor-infiltrating CD8 lymphocytes in B16 melanoma tumors with single-cell RNA-Seq. OncoImmunology 9, 1737369 (2020).","journal-title":"OncoImmunology"},{"key":"74125_CR98","doi-asserted-by":"publisher","first-page":"vbac016","DOI":"10.1093\/bioadv\/vbac016","volume":"2","author":"P Badia-i-Mompel","year":"2022","unstructured":"Badia-i-Mompel, P. et al. decoupleR: ensemble of computational methods to infer biological activities from omics data. Bioinform. Adv. 2, vbac016 (2022).","journal-title":"Bioinform. Adv."},{"key":"74125_CR99","doi-asserted-by":"publisher","unstructured":"Muzellec, B., Tele\u0144czuk, M., Cabeli, V. & Andreux, M. PyDESeq2: a python package for bulk RNA-seq differential expression analysis. bioRxiv https:\/\/doi.org\/10.1101\/2022.12.14.520412 (2022).","DOI":"10.1101\/2022.12.14.520412"},{"key":"74125_CR100","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1093\/bioinformatics\/bty895","volume":"35","author":"A Zhu","year":"2018","unstructured":"Zhu, A., Ibrahim, J. G. & Love, M. I. Heavy-tailed prior distributions for sequence count data: removing the noise and preserving large differences. Bioinformatics 35, 2084\u20132092 (2018).","journal-title":"Bioinformatics"},{"key":"74125_CR101","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/s41586-018-0414-6","volume":"560","author":"GL Manno","year":"2018","unstructured":"Manno, G. L. et al. RNA velocity of single cells. Nature 560, 494\u2013498 (2018).","journal-title":"Nature"},{"key":"74125_CR102","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41587-020-0591-3","volume":"38","author":"V Bergen","year":"2020","unstructured":"Bergen, V., Lange, M., Peidli, S., Wolf, F. A. & Theis, F. J. Generalizing RNA velocity to transient cell states through dynamical modeling. Nat. Biotechnol. 38, 1408\u20131414 (2020).","journal-title":"Nat. Biotechnol."},{"key":"74125_CR103","doi-asserted-by":"publisher","unstructured":"Kleshchevnikov, V. et al. Cell2location maps fine-grained cell types in spatial transcriptomics. Nat. Biotechnol.https:\/\/doi.org\/10.1038\/s41587-021-01139-4 (2022).","DOI":"10.1038\/s41587-021-01139-4"},{"key":"74125_CR104","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","volume":"16","author":"I Korsunsky","year":"2019","unstructured":"Korsunsky, I. et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods 16, 1289\u20131296 (2019).","journal-title":"Nat. Methods"},{"key":"74125_CR105","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/s41587-019-0113-3","volume":"37","author":"B Hie","year":"2019","unstructured":"Hie, B., Bryson, B. & Berger, B. Efficient integration of heterogeneous single-cell transcriptomes using Scanorama. Nat. Biotechnol. 37, 685\u2013691 (2019).","journal-title":"Nat. Biotechnol."},{"key":"74125_CR106","first-page":"2041","volume":"45","author":"F Pedregosa","year":"2012","unstructured":"Pedregosa, F. et al. Scikit-learn: machine learning in Python. arXiv 45, 2041\u20132049 (2012).","journal-title":"arXiv"},{"key":"74125_CR107","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nbt.3192","volume":"33","author":"R Satija","year":"2015","unstructured":"Satija, R., Farrell, J. A., Gennert, D., Schier, A. F. & Regev, A. Spatial reconstruction of single-cell gene expression data. Nat. Biotechnol. 33, 495\u2013502 (2015).","journal-title":"Nat. Biotechnol."},{"key":"74125_CR108","doi-asserted-by":"publisher","first-page":"10934","DOI":"10.1093\/nar\/gkad841","volume":"51","author":"S M\u00fcller-Dott","year":"2023","unstructured":"M\u00fcller-Dott, S. et al. Expanding the coverage of regulons from high-confidence prior knowledge for accurate estimation of transcription factor activities. Nucleic Acids Res. 51, 10934\u201310949 (2023).","journal-title":"Nucleic Acids Res"},{"key":"74125_CR109","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1126\/science.1254257","volume":"344","author":"AP Patel","year":"2014","unstructured":"Patel, A. P. et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344, 1396\u20131401 (2014).","journal-title":"Science"},{"key":"74125_CR110","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41592-019-0686-2","volume":"17","author":"P Virtanen","year":"2020","unstructured":"Virtanen, P. et al. SciPy 1.0: fundamental algorithms for scientific computing in Python. Nat. Methods 17, 261\u2013272 (2020).","journal-title":"Nat. Methods"},{"key":"74125_CR111","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41592-024-02212-x","volume":"22","author":"L Marconato","year":"2025","unstructured":"Marconato, L. et al. SpatialData: an open and universal data framework for spatial omics. Nat. Methods 22, 58\u201362 (2025).","journal-title":"Nat. Methods"},{"key":"74125_CR112","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41587-021-01094-0","volume":"40","author":"NF Greenwald","year":"2022","unstructured":"Greenwald, N. F. et al. Whole-cell segmentation of tissue images with human-level performance using large-scale data annotation and deep learning. Nat. Biotechnol. 40, 555\u2013565 (2022).","journal-title":"Nat. Biotechnol."},{"key":"74125_CR113","doi-asserted-by":"crossref","unstructured":"Van der Walt, S. et al. scikit-image: Image processing in Python. PeerJ 2, e453 (2014).","DOI":"10.7717\/peerj.453"},{"key":"74125_CR114","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/s41592-021-01358-2","volume":"19","author":"G Palla","year":"2022","unstructured":"Palla, G. et al. Squidpy: a scalable framework for spatial omics analysis. Nat. Methods 19, 171\u2013178 (2022).","journal-title":"Nat. Methods"},{"key":"74125_CR115","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.21105\/joss.01317","volume":"4","author":"C Davidson-Pilon","year":"2019","unstructured":"Davidson-Pilon, C. Lifelines: survival analysis in Python. J. Open Source Softw. 4, 1317 (2019).","journal-title":"J. Open Source Softw."},{"key":"74125_CR116","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1109\/MCSE.2007.55","volume":"9","author":"JD Hunter","year":"2007","unstructured":"Hunter, J. D. Matplotlib: a 2D graphics environment. Comput. Sci. Eng. 9, 90\u201395 (2007).","journal-title":"Comput. Sci. Eng."},{"key":"74125_CR117","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.21105\/joss.03021","volume":"6","author":"M Waskom","year":"2021","unstructured":"Waskom, M. seaborn: statistical data visualization. J. Open Source Softw. 6, 3021 (2021).","journal-title":"J. Open Source Softw."},{"key":"74125_CR118","doi-asserted-by":"publisher","unstructured":"T\u00far\u00f3s, D. et al. Spatial transcriptomics datasets for \u201cSpatiotemporal organisation of residual disease in mouse and human BRCA1-deficient mammary tumours and breast cancer.\u201d Zenodo: https:\/\/doi.org\/10.5281\/zenodo.15102983 (2025).","DOI":"10.5281\/zenodo.15102983"},{"key":"74125_CR119","doi-asserted-by":"publisher","unstructured":"T\u00far\u00f3s, D. et al. Single-cell RNA sequencing datasets for \u201cSpatiotemporal organisation of residual disease in mouse and human BRCA1-deficient mammary tumours and breast cancer.\u201d Zenodo: https:\/\/doi.org\/10.5281\/zenodo.15103411 (2025).","DOI":"10.5281\/zenodo.15103411"},{"key":"74125_CR120","doi-asserted-by":"publisher","unstructured":"T\u00far\u00f3s, D. et al. IMC datasets for \u201cSpatiotemporal organisation of residual disease in mouse and human BRCA1-deficient mammary tumours and breast cancer.\u201d Zenodo: 15096025 https:\/\/doi.org\/10.5281\/zenodo.15096025 (2025).","DOI":"10.5281\/zenodo.15096025"},{"key":"74125_CR121","doi-asserted-by":"publisher","unstructured":"T\u00far\u00f3s, D. et al. GitHub Repository for Single-cell RNA sequencing datasets for \u201cSpatiotemporal organisation of residual disease in mouse and human BRCA1-deficient mammary tumours and breast cancer.\u201d GitHub https:\/\/doi.org\/10.5281\/zenodo.19365629. (2026).","DOI":"10.5281\/zenodo.19365629"},{"key":"74125_CR122","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.3390\/cells12111462","volume":"12","author":"K Zappe","year":"2023","unstructured":"Zappe, K. et al. Aberrant DNA methylation, expression, and occurrence of transcript variants of the ABC transporter ABCA7 in breast cancer. Cells 12, 1462 (2023).","journal-title":"Cells"},{"key":"74125_CR123","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14777-0","volume":"11","author":"SD Praktiknjo","year":"2020","unstructured":"Praktiknjo, S. D. et al. Tracing tumorigenesis in a solid tumor model at single-cell resolution. Nat. Commun. 11, 991 (2020).","journal-title":"Nat. Commun."},{"key":"74125_CR124","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.prostaglandins.2017.01.002","volume":"132","author":"R Tian","year":"2017","unstructured":"Tian, R. et al. ALOX15 as a suppressor of inflammation and cancer: lost in the link. Prostaglandins Other Lipid Mediat 132, 77\u201383 (2017).","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"74125_CR125","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.1007\/s00262-023-03496-2","volume":"72","author":"MDM Maldonado","year":"2023","unstructured":"Maldonado, M. D. M., Schlom, J. & Hamilton, D. H. Blockade of tumor-derived colony-stimulating factor 1 (CSF1) promotes an immune-permissive tumor microenvironment. Cancer Immunol., Immunother. 72, 3349\u20133362 (2023).","journal-title":"Cancer Immunol., Immunother."},{"key":"74125_CR126","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-14575-2","volume":"12","author":"L Yi","year":"2022","unstructured":"Yi, L. et al. NTN4 as a prognostic marker and a hallmark for immune infiltration in breast cancer. Sci. Rep. 12, 10567 (2022).","journal-title":"Sci. Rep."},{"key":"74125_CR127","doi-asserted-by":"publisher","unstructured":"Geiger, R. et al. RNF19B confers tumor resistance to CAR T cells. https:\/\/doi.org\/10.21203\/rs.3.rs-7847831\/v1 (2025).","DOI":"10.21203\/rs.3.rs-7847831\/v1"},{"key":"74125_CR128","doi-asserted-by":"publisher","first-page":"1258951","DOI":"10.3389\/fonc.2023.1258951","volume":"13","author":"S Zhang","year":"2023","unstructured":"Zhang, S., Cai, Z. & Li, H. AHNAKs roles in physiology and malignant tumors. Front. Oncol. 13, 1258951 (2023).","journal-title":"Front. Oncol."},{"key":"74125_CR129","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1158\/2159-8290.CD-20-0288","volume":"10","author":"C Liao","year":"2020","unstructured":"Liao, C. et al. Identification of BBOX1 as a therapeutic target in triple-negative breast cancer. Cancer Discov. 10, 1706\u20131721 (2020).","journal-title":"Cancer Discov."},{"key":"74125_CR130","doi-asserted-by":"publisher","first-page":"114672","DOI":"10.1016\/j.bcp.2021.114672","volume":"192","author":"S Leu","year":"2021","unstructured":"Leu, S. The role and regulation of Pnn in proliferative and non-dividing cells: form embryogenesis to pathogenesis. Biochem. Pharmacol. 192, 114672 (2021).","journal-title":"Biochem. Pharmacol."},{"key":"74125_CR131","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-022-02494-1","volume":"22","author":"L Li","year":"2022","unstructured":"Li, L. et al. FERMT1 contributes to the migration and invasion of nasopharyngeal carcinoma through epithelial\u2013mesenchymal transition and cell cycle arrest. Cancer Cell Int. 22, 70 (2022).","journal-title":"Cancer Cell Int"},{"key":"74125_CR132","doi-asserted-by":"publisher","first-page":"110775","DOI":"10.1016\/j.cellsig.2023.110775","volume":"109","author":"R Liu","year":"2023","unstructured":"Liu, R. et al. STNM1 in human cancers: role, function and potential therapy sensitizer. Cell. Signal. 109, 110775 (2023).","journal-title":"Cell. Signal."},{"key":"74125_CR133","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39901-8","volume":"14","author":"Z Yang","year":"2023","unstructured":"Yang, Z. et al. ACTL6A protects gastric cancer cells against ferroptosis through induction of glutathione synthesis. Nat. Commun. 14, 4193 (2023).","journal-title":"Nat. Commun."},{"key":"74125_CR134","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/s43018-021-00266-w","volume":"2","author":"S Adam","year":"2021","unstructured":"Adam, S. et al. The CIP2A\u2013TOPBP1 axis safeguards chromosome stability and is a synthetic lethal target for BRCA-mutated cancer. Nat. Cancer 2, 1357\u20131371 (2021).","journal-title":"Nat. Cancer"},{"key":"74125_CR135","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.phrs.2017.02.011","volume":"119","author":"Y Tu","year":"2017","unstructured":"Tu, Y., Johnstone, C. N. & Stewart, A. G. Annexin A1 influences in breast cancer: Controversies on contributions to tumour, host and immunoediting processes. Pharmacol. Res. 119, 278\u2013288 (2017).","journal-title":"Pharmacol. Res."},{"key":"74125_CR136","doi-asserted-by":"publisher","first-page":"5404","DOI":"10.7150\/jca.57880","volume":"12","author":"C Zhang","year":"2021","unstructured":"Zhang, C., Hu, H., Wang, X., Zhu, Y. & Jiang, M. WFDC protein: a promising diagnosis biomarker of ovarian cancer. J. Cancer 12, 5404\u20135412 (2021).","journal-title":"J. Cancer"},{"key":"74125_CR137","doi-asserted-by":"publisher","first-page":"13","DOI":"10.18632\/aging.101372","volume":"10","author":"LL Munn","year":"2018","unstructured":"Munn, L. L. & Garkavtsev, I. SLPI: a new target for stopping metastasis. Aging (Albany NY) 10, 13\u201314 (2018).","journal-title":"Aging (Albany NY)"},{"key":"74125_CR138","doi-asserted-by":"publisher","first-page":"653","DOI":"10.3390\/cells10030653","volume":"10","author":"M Oshi","year":"2021","unstructured":"Oshi, M. et al. Annexin A1 expression is associated with epithelial\u2013mesenchymal transition (EMT), cell proliferation, prognosis, and drug response in pancreatic cancer. Cells 10, 653 (2021).","journal-title":"Cells"},{"key":"74125_CR139","doi-asserted-by":"publisher","first-page":"5261","DOI":"10.1158\/0008-5472.CAN-12-0254","volume":"72","author":"M Shiota","year":"2012","unstructured":"Shiota, M. et al. Clusterin mediates TGF-\u03b2\u2013Induced epithelial\u2013mesenchymal transition and metastasis via twist1 in prostate cancer cells. Cancer Res. 72, 5261\u20135272 (2012).","journal-title":"Cancer Res"},{"key":"74125_CR140","doi-asserted-by":"publisher","first-page":"e62347","DOI":"10.1371\/journal.pone.0062347","volume":"8","author":"RD Bennett","year":"2013","unstructured":"Bennett, R. D., Pittelkow, M. R. & Strehler, E. E. Immunolocalization of the tumor-sensitive calmodulin-like protein CALML3 in normal human skin and hyperproliferative skin disorders. PLoS ONE 8, e62347 (2013).","journal-title":"PLoS ONE"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74125-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74125-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74125-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:19:13Z","timestamp":1785518353000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74125-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":140,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["74125"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-74125-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"assertion":[{"value":"16 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.V. is currently employed by F. Hoffmann-La Roche Ltd. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"7456"}}